Skip to main content
Premium Trial:

Request an Annual Quote

Diagnostic Products Corporation Gets License to Compugen Prostate Proteins

NEW YORK, Jan. 22-Compugen has granted a license to Diagnostic Products Corporation to develop new assays for prostate cancer, the two companies said today.

 

The license, which covers two previously unidentified prostate-specific proteins, gives DPC the exclusive right to develop and commercialize assays for screening, detection and monitoring of cancer.

 

Compugen will receive milestone payments and royalties in the deal.

 

Compugen announced that it had discovered these two proteins last February. Both are encoded by mRNA splice variants of the genes for prostate-specific antigen.

 

Financial details of this agreement were not disclosed.

 

Diagnostic Products Corporation, based in Los Angeles, produces immunodiagnostic tests and manufactures laboratory instruments for diagnostics.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.